Noya A, Anat S, Shaul S, Miriam A, Einat P
Harm Reduct J. 2024; 21(1):55.
PMID: 38429780
PMC: 10905817.
DOI: 10.1186/s12954-024-00970-7.
Bouck Z, Scheim A, Gomes T, Ling V, Caudarella A, Werb D
Int J Drug Policy. 2022; 104:103680.
PMID: 35447476
PMC: 9005368.
DOI: 10.1016/j.drugpo.2022.103680.
Marks M, Scheibe A, Shelly S
Harm Reduct J. 2020; 17(1):25.
PMID: 32295595
PMC: 7161298.
DOI: 10.1186/s12954-020-00368-1.
Tan J, Altice F, Madden L, Zelenev A
Lancet HIV. 2019; 7(2):e121-e128.
PMID: 31879250
PMC: 7289179.
DOI: 10.1016/S2352-3018(19)30373-X.
Shulman M, Wai J, Nunes E
CNS Drugs. 2019; 33(6):567-580.
PMID: 31062259
PMC: 6585403.
DOI: 10.1007/s40263-019-00637-z.
Estimating HIV and HCV prevalence among people who inject drugs in 5 Ukrainian cities using stratification-based respondent driven and random sampling.
Zelenev A, Shea P, Mazhnaya A, Meteliuk A, Pykalo I, Marcus R
Int J Drug Policy. 2018; 67:91-101.
PMID: 30503695
PMC: 6537868.
DOI: 10.1016/j.drugpo.2018.09.010.
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine.
Mazhnaya A, Marcus R, Bojko M, Zelenev A, Makarenko I, Pykalo I
J Acquir Immune Defic Syndr. 2018; 79(3):288-295.
PMID: 30312275
PMC: 8215524.
DOI: 10.1097/QAI.0000000000001827.
Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine.
Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R
Drug Alcohol Depend. 2018; 190:82-88.
PMID: 29990648
PMC: 6292439.
DOI: 10.1016/j.drugalcdep.2018.05.027.
Hepatitis C virus status awareness and test results confirmation among people who inject drugs in Ukraine.
Iakunchykova O, Meteliuk A, Zelenev A, Mazhnaya A, Tracy M, Altice F
Int J Drug Policy. 2018; 57:11-17.
PMID: 29655101
PMC: 5994183.
DOI: 10.1016/j.drugpo.2018.03.022.
Concurrent drug injection during opioid agonist treatment among people who inject drugs in Ukraine.
Makarenko I, Mazhnaya A, Marcus R, Pykalo I, Madden L, Filippovich S
J Subst Abuse Treat. 2018; 87:1-8.
PMID: 29471921
PMC: 5826566.
DOI: 10.1016/j.jsat.2018.01.007.
Retention in medication-assisted treatment programs in Ukraine-Identifying factors contributing to a continuing HIV epidemic.
Dumchev K, Dvoryak S, Chernova O, Morozova O, Altice F
Int J Drug Policy. 2017; 48:44-53.
PMID: 28800420
PMC: 5603251.
DOI: 10.1016/j.drugpo.2017.05.014.
Willingness to pay for opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Makarenko I, Mazhnaya A, Marcus R, Bojko M, Madden L, Filippovich S
Int J Drug Policy. 2017; 45:56-63.
PMID: 28628853
PMC: 5533603.
DOI: 10.1016/j.drugpo.2017.05.037.
Primary healthcare-based integrated care with opioid agonist treatment: First experience from Ukraine.
Morozova O, Dvoriak S, Pykalo I, Altice F
Drug Alcohol Depend. 2017; 173:132-138.
PMID: 28242537
PMC: 5545131.
DOI: 10.1016/j.drugalcdep.2016.12.025.
Retention in Georgia opioid substitution therapy program and associated factors.
Ruadze E, Todadze K
Harm Reduct J. 2016; 13(1):35.
PMID: 27931232
PMC: 5146853.
DOI: 10.1186/s12954-016-0124-z.
In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.
Mazhnaya A, Bojko M, Marcus R, Filippovych S, Islam Z, Dvoriak S
Drugs (Abingdon Engl). 2016; 23(2):163-175.
PMID: 27458326
PMC: 4957015.
DOI: 10.3109/09687637.2015.1127327.
Factors associated with physical and sexual violence by police among people who inject drugs in Ukraine: implications for retention on opioid agonist therapy.
Kutsa O, Marcus R, Bojko M, Zelenev A, Mazhnaya A, Dvoriak S
J Int AIDS Soc. 2016; 19(4 Suppl 3):20897.
PMID: 27435717
PMC: 4951533.
DOI: 10.7448/IAS.19.4.20897.
Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
Makarenko I, Mazhnaya A, Polonsky M, Marcus R, Bojko M, Filippovych S
Drug Alcohol Depend. 2016; 165:213-20.
PMID: 27370527
PMC: 5094181.
DOI: 10.1016/j.drugalcdep.2016.06.011.
The Future of Opioid Agonist Therapies in Ukraine: A Qualitative Assessment of Multilevel Barriers and Ways Forward to Promote Retention in Treatment.
Bojko M, Mazhnaya A, Marcus R, Makarenko I, Islam Z, Filippovych S
J Subst Abuse Treat. 2016; 66:37-47.
PMID: 27211995
PMC: 4919997.
DOI: 10.1016/j.jsat.2016.03.003.
"Bureaucracy & Beliefs": Assessing the Barriers to Accessing Opioid Substitution Therapy by People Who Inject Drugs in Ukraine.
Bojko M, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z
Drugs (Abingdon Engl). 2016; 22(3):255-262.
PMID: 27087758
PMC: 4831711.
DOI: 10.3109/09687637.2015.1016397.
Pharmacological induction of CCL5 in vivo prevents gp120-mediated neuronal injury.
Campbell L, Avdoshina V, Day C, Lim S, Mocchetti I
Neuropharmacology. 2015; 92:98-107.
PMID: 25623966
PMC: 4346538.
DOI: 10.1016/j.neuropharm.2015.01.009.